Brief: Eris Lifesciences Ltd Launchs Generic Semaglutide Under The Brand ‘Sundae’ In India
March 20 (Reuters) - Eris Lifesciences Ltd ERIS.NS: ERIS LIFESCIENCES LTD - LAUNCHS GENERIC SEMAGLUTIDE UNDER THE BRAND ‘SUNDAE’ IN INDIA. ERIS LIFESCIENCES - INTRODUCING SUNDAE IN MULTI-DOSE VIAL FORMATS STARTING AT 1,290 RUPEES PER MONTH Source text: [ID:] Further company coverage: ERIS.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eris Lifesciences
See all newsIndia's Eris Lifesciences gains on strong quarterly results
Brief: Eris Lifesciences Sept-Quarter Consol Net Profit 1.84 Billion Rupees
Brief: Eris Lifesciences Says Krishnakumar Vaidyanathan Resigns As Executive Director & COO
Brief: Eris Lifesciences Ltd Says June-Quarter Consol Net Profit 1.42 Billion Rupees
Brief: Eris Lifesciences March-Quarter Consol Net Profit 2.82 Billion Rupees